---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-25-001238"
form_type: "8-K"
ticker: "LCTC"
cik: "0001493137"
company_name: "Lifeloc Technologies, Inc"
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:22:37.759670+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lifeloc Q2 2025 net loss $(394k), revenue -7% YoY; SpinDx beta testing begins, launch expected early 2026

## Summary
- Net revenue $2.219M, down 7% YoY; net loss $(394k) ($0.14 loss per share) vs $(298k) loss in Q2 2024.
- Gross margin stable at 41.7%; R&D spend $623k primarily on SpinDx drug testing platform.
- SpinDx beta testing underway for delta-9-THC detection; commercial launch targeted for early 2026.
- Company began trading on OTCID tier of OTC Markets effective July 1, 2025.

## SEC filing metadata
- accession: 0001079973-25-001238
- form_type: 8-K
- ticker: LCTC
- cik: 0001493137
- company_name: Lifeloc Technologies, Inc
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1493137/000107997325001238/0001079973-25-001238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1493137/000107997325001238/lctc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-25-001238
- JSON: https://secwatch.observer/filing/0001079973-25-001238.json
- Plain text: https://secwatch.observer/filing/0001079973-25-001238.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.